STOCK TITAN
  1. Home
  2. Sec-filings
  3. MYGN
  4. [Form 4] MYRIAD GENETICS INC Insider Trading Activity

Myriad Genetics (MYGN) CLO granted 195,876 RSUs and has shares withheld

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MYRIAD GENETICS INC Chief Legal Officer Jennifer Lynne Fox reported equity compensation and related tax withholding transactions in company common stock. On March 12, 2026, she acquired 195,876 time-based restricted stock units granted under the 2017 Employee, Director and Consultant Equity Incentive Plan, with each unit representing one share of common stock that vests in three equal annual installments beginning on the first anniversary of the grant date. On March 13, 2026, 5,995 shares were withheld by the company at a price of $4.66 per share to satisfy tax obligations related to previously vesting restricted stock units. Following these transactions, she directly holds 310,362 shares of common stock.

Positive

  • None.

Negative

  • None.
Insider Fox Jennifer Lynne
Role Chief Legal Officer
Type Security Shares Price Value
Tax Withholding Common Stock 5,995 $4.66 $28K
Grant/Award Common Stock 195,876 $0.00 --
Holdings After Transaction: Common Stock — 310,362 shares (Direct)
Footnotes (1)
  1. Consists of time-based restricted stock units granted pursuant to the Issuer's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Fox Jennifer Lynne
(Last) (First) (Middle)
322 NORTH 2200 WEST
(Street)
SALT LAKE CITY UT 84116
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Legal Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/12/2026 A 195,876(1) A $0 316,357 D
Common Stock 03/13/2026 F 5,995(2) D $4.66 310,362 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Consists of time-based restricted stock units granted pursuant to the Issuer's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date.
2. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026.
Remarks:
By: Justin Hunter For: Jennifer Lynne Fox 03/16/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How do the MYGN restricted stock units granted to Jennifer Lynne Fox vest?

The 195,876 restricted stock units vest in three equal annual installments. Vesting starts on the first anniversary of the grant date, and each vested unit converts into one share of Myriad Genetics common stock, aligning compensation with long-term company performance.

Why were 5,995 MYGN shares withheld from Jennifer Lynne Fox?

The 5,995 shares of Myriad Genetics common stock were withheld to satisfy tax withholding obligations. The withholding related to the vesting of previously granted restricted stock units and was calculated using the closing stock price of $4.66 on March 13, 2026.

What is Jennifer Lynne Fox’s MYGN share ownership after these transactions?

After the reported grant and tax-withholding disposition, Jennifer Lynne Fox directly owns 310,362 shares of Myriad Genetics common stock. This figure reflects her position following the award of 195,876 restricted stock units and the withholding of 5,995 shares for taxes.